The blood pressure does not affect the heart fatty acid binding protein in the blood of patients on hemodialysis

Sabaheta Hasic, Radivoj Jadrić, Emina Kiseljaković, Nesina Avdagić, Amela Bečiragić, Miran Hadžiahmetović, Mirad Hujdur, Adela Šabić, Larisa Ščetić Mešan, Almira Hadžović-Džuvo

Abstract


Objectives: We hypothesized that serum heart fatty acid binding protein (HFABP) levels could be affected by hypertension in addition to renal impairment in patients on hemodialysis. The aim was to find out possible association between serum HFABP and hypertension in patients treated by hemodialysis.

Methods: The cross-sectional study included 72 patients, both gender, age 18-78 years who were recruited from Clinic for Hemodialysis, University Clinical Center Sarajevo. According to Kidney Disease Outcomes Quality Initiative criteria for hypertension, patients were distributed into 2 groups: normotensive (HD-N) and hypertensive (HD-H) group. The cardiac biomarker HFABP was measured using ELISA kit Human FABP3 (Elabscience Biotechnology Co.,Ltd), on immunoanalyzer STAT FAX 2100, USA. The kidney functional biomarkers were measured spectrophotometrically using automated analyzer.

Results: Serum HFABP level was lower in HD-H group (3.02(1.96-4.13) ng/mL) compared to serum HFABP in HD-N group (3.38(1.98-5.37) ng/mL)(p=0.359). Patients in HD-N group were older and treated by hemodialysis for a longer time than those in HD-H group (p<0.001 and p=0.029, respectively).

Conclusion: Serum HFABP level in normotensive patients on hemodialysis is not significantly different compared to hypertensive patients suggesting that heart type fatty acid binding protein might not be significantly affected by hypertension in hemodialysis patients.

Keywords: HFABP, hemodialysis, blood pressure, cardiovascular risk


Full Text:

PDF

References


Smathers RL, Petersen DR. The human fatty acidbinding protein family: evolutionary divergences and functions. Hum Genomics. 2011; 5(3):170-91.

Vupputuri A, Sekhar S, Krishnan S, Venugopal K, Natarajan KU. Heart-type fatty acid-binding protein (HFABP) as an early diagnostic biomarker in patients with acute chest pain. Indian Heart J. 2015; 67(6):538-42.

Erenler AK, Yardan T, Duran L, Baydin A.Usefulness of heart-type fatty acid binding protein in the emergency department.J Pak Med Assoc. 2013; 63(9):1176-81.

Al-Hadi HA, William B, Fox KA. Serum Level of Heart-Type Fatty Acid-Binding Protein in Patients with Chronic Renal Failure. Sultan Qaboos University Medical Journal. 2009; 9(3):311-314.

Otaki Y, Watanabe T, Takahashi H, Hirayama A, Narumi T, Kadowaki S, et al. Association of heart-type fatty acid-binding protein with cardiovascular risk factors and all-cause mortality in the general population: the Takahata study. PloS one. 2014; 9(5):e94834.

KDIGO IGO. Blood Pressure Work Group. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease: Kidney Disease; 2012 [cited 2016 29. 08.].

Gutiérrez-Adrianzén OA, Moraes ME, Almeida AP, Lima JW, Marinho MF, Marques AL, et al. Pathophysiological, cardiovascular and neuroendocrine changes in hypertensive patients during the hemodialysis session. J Hum Hypertens. 2015; 29(6):366-72.

Ekart R, Kanič V, Pečovnik-Balon B, Bevc S, Dvoršak B, Hojs R. Blood pressure measurements and left ventricular mass index in hemodialysis patients. Artif Organs. 2012; 36(6):517-24. .

Sebastian S, Filmalter C, Harvey J, Chothia MY. Intradialytic hypertension during chronic hemodialysis and subclinical fluid overload assessed by bioimpedance spectroscopy. Clinical Kidney Journal. 2016; 9(4):636-43.

Ishimura S, Furuhashi M, Watanabe Y, Hoshina K, Fuseya T, Mita T, et al. Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general population. PloS one. 2013; 8(11):e81318.

Bjurman C, Petzold M, Venge P, Farbemo J, Fu ML, Hammarsten O. High-sensitive cardiac troponin, NT-proBNP, hFABP and copeptin levels in relation to glomerular filtration rates and a medical record of cardiovascular disease. Clinical biochemistry. 2015; 48(4-5):302-7.

Nayashida N, Chihara S, Tayama E, Akasu K, Kai E, Kawara T, et al. Influence of renal function on serum and urinary heart fatty acid-binding protein levels. The Journal of cardiovascular surgery. 2001; 42(6):735-40.

Al-Hadi HA, William B, Fox KA. Serum level of heart-type Fatty Acid-binding protein in patients with chronic renal failure. Sultan Qaboos University medical journal. 2009; 9(3):311-4.

Dihazi H, Koziolek MJ, Datta RR, Wallbach M, Jung K, Heise D et al. FABP1 and FABP3 Have High Predictive Values for Renal Replacement Therapy in Patients with Acute Kidney Injury. Blood purification. 2016; 42(3):202-13.

Karbek B, Özbek M, Bozkurt NC, Ginis Z, Güngünes A, Ünsal İÖ, et al. Heart-Type Fatty Acid Binding Protein (HFABP): Relationship with arterial ıntima-media thickness and role as diagnostic marker for atherosclerosis in patients with ımpaired glucose metabolism.Cardiovasc Diabetol. 2011; 10:37.

Anand S, Tamura MK, Chertow GM. The elderly patients on hemodialysis. Minerva Urol Nefrol. 2010; 62(1):87–101.

Glatz JFC, Mohren R. Plasma reference value of heart-type fatty acid-binding protein, the earliest available plasma biomarker of acute myocardial infarction. 2013; 5(8):1206-1209.

Niizeki T, Takeishi Y, Takabatake N, Shibata Y, Konta T, Kato T, et al.Circulating levels of heart-type fatty acid-binding protein in a general Japanese population: effects of age, gender, and physiologic characteristics. Circ J. 2007; 71(9):1452-7.


Refbacks

  • There are currently no refbacks.